May patients receiving 5-alpha-reductase inhibitors be in higher risk of COVID-19 complications?-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

May patients receiving 5-alpha-reductase inhibitors be in higher risk of COVID-19 complications?

Published:2020-07 Issue: Volume:140 Page:109751
ISSN:0306-9877
Container-title:Medical Hypotheses
language:en
Short-container-title:Medical Hypotheses

Author:

Adamowicz Jan,Juszczak Kajetan,Drewa Tomasz

Publisher

Elsevier BV

Subject

General Medicine

Reference13 articles.

1. 2019 novel coronavirus patients’ clinical characteristics, discharge rate and fatality rate of meta-analysis;Li;J Med Virol,2020

2. Sex difference and smoking predisposition in patients with COVID-19. Lancet;Cai;Respir Med,2020

3. Andriole GL. The use of 5-alpha reductase inhibitors in the treatment of benign prostatic hyperplasia. Asian;Kim;J Urol,2018

4. The role of dihydrotestosterone in benign prostatic hyperplasia;Carson;Urology,2003

5. The 5 alpha-reductase isozyme family: a review of basic biology and their role in human diseases;Azzouni;Adv Urol,2012

Cited by 10 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Are herbal medications, with possible beneficial effects for benign prostatic hyperplasia, better to be continued during the COVID-19 pandemic?;Urologia Journal;2023-04-17

2. Clinical findings post hospital discharge in patients with covid-19: A telephone interview study;MOJ Public Health;2021-09-27

3. Testosterone in COVID-19: An Adversary Bane or Comrade Boon;Frontiers in Cellular and Infection Microbiology;2021-09-08

4. Androgenetic alopecia and COVID ‐19: A review of the hypothetical role of androgens;Dermatologic Therapy;2021-06-09

5. Is COVID-19 a risk factor for progression of benign prostatic hyperplasia and exacerbation of its related symptoms?: a systematic review;Prostate Cancer and Prostatic Diseases;2021-05-18

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3